Summary
Danaher Corporation reported a 7.0% decrease in total sales for the first quarter of 2023 compared to the prior year, with core sales down 4.0%. This decline was primarily driven by reduced demand for COVID-19 related products, particularly in the Biotechnology and Diagnostics segments, as well as the impact of unfavorable currency exchange rates. Net earnings attributable to common stockholders were $1.4 billion, or $1.94 per diluted share, down from $1.7 billion, or $2.31 per diluted share, in the first quarter of 2022. Despite the overall sales decrease, the Environmental & Applied Solutions segment showed a 5.0% increase in total sales, driven by strong performance in its water quality businesses. The company is progressing with its plan to separate the Environmental & Applied Solutions segment into a new publicly traded company, Veralto Corporation, in the fourth quarter of 2023. Danaher maintains a strong liquidity position with $7.4 billion in cash and cash equivalents as of March 31, 2023, and continues to generate substantial operating cash flow, which management believes is sufficient to fund operations, acquisitions, and shareholder returns.
Financial Highlights
50 data points| Revenue | $5.95B |
| Cost of Revenue | $2.29B |
| Gross Profit | $3.66B |
| R&D Expenses | $373.00M |
| SG&A Expenses | $1.77B |
| Operating Income | $1.52B |
| Interest Expense | $66.00M |
| Net Income | $1.43B |
| EPS (Basic) | $1.96 |
| EPS (Diluted) | $1.94 |
| Shares Outstanding (Basic) | 729.40M |
| Shares Outstanding (Diluted) | 737.20M |
Key Highlights
- 1Total sales declined 7.0% to $7.17 billion in Q1 2023 compared to $7.69 billion in Q1 2022, with core sales down 4.0%.
- 2Net earnings decreased to $1.4 billion ($1.94 per diluted share) from $1.7 billion ($2.31 per diluted share) year-over-year, impacted by lower core sales and currency headwinds.
- 3The Biotechnology segment experienced a significant 16.0% total sales decline (13.0% core sales decline), primarily due to reduced demand for COVID-19 therapeutics and vaccine-related products and inventory repurposing by customers.
- 4The Diagnostics segment saw a 10.0% total sales decrease (7.5% core sales decrease), largely attributed to lower demand for COVID-19 molecular diagnostic tests.
- 5The Environmental & Applied Solutions segment was a bright spot, with total sales increasing 5.0% (6.5% core sales growth), driven by strong performance in water quality businesses.
- 6The planned separation of the Environmental & Applied Solutions business (to become Veralto Corporation) is on track for completion in Q4 2023.
- 7The company ended the quarter with $7.4 billion in cash and cash equivalents, and operating cash flow remained strong at $1.95 billion, indicating robust liquidity.